The state of the IP union

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The state of the IP union

Alice was the dominant topic in the AIPLA session "Addressing the Hot Topics of Today for Tomorrow's Business"

The first question that moderator Timothy Meigs of Beckton Dickinson asked the State of the IP Union Panel yesterday was: what keeps them and their clients up at night? The panel's subtitle was "Addressing the Hot Topics of Today for Tomorrow's Business," but the answer to this question was hardly a hot and fresh one: it's still Alice.

Philip Petti of USG Corporation commented: "It's sort of like we're sitting in the middle of the bus, and there's a crazy person at the wheel." Petti says he and his company feel the "reverberations" of the uncertainty brought on by Alice. From the statistics he's examined, "if our patents are tested, about 70% of them are going to fail," he said. "How do I advise my business people when I tell them we're going to put so much money into patenting that you can't even count on?"

As Microsoft's Micky Minhas sees it, Alice may be dissuading IP owners from other countries from patenting their products here, placing the US at a disadvantage. As China considers accepting patents for business methods, the US is heading "in the opposite direction," he said.

Pfizer's Adrian Looney praised Hatch-Waxman and the BPCIA for clearing the way for generics. But he also questioned whether, if the Alice decision had been handed down before the boom of generics, those pharmaceuticals that have saved many lives would even exist today. It was suggested that it is not just innovation in the biopharma space that Alice stands to inhibit. Qualcomm's Laurie Self said that funding for startups "depends on the VC community believing that you have a predictable right, an enforceable right." She added: "I really do worry that, through this constant diminishment of patent rights, you're making long-term research too risky an investment for startups."

Looney also pointed to the specificity of Hatch-Waxman litigation to one industry as a potential model for reform to 101 issues, which have been treated very inconsistently by the courts. Frustrating though the denial of cert for a number of recent 101 cases is, the panel conceded the Supreme Court has heard a number of IP cases and may still want to see the lower courts shake it out.

more from across site and SHARED ros bottom lb

More from across our site

Monetisation is standing at the forefront of patent development, and one firm says AI is increasingly being deployed
Data centres are being built across the US, prompting patent disputes, but Texas’s thriving tech industry and patent-ready courts make the state particularly ‘ripe’ for litigation
Carpmaels & Ransford is set to bolster its UK attorney team with the appointment of Simmons & Simmons’s head of IP in the UK
Updates on Nokia’s licensing strides and a surge in patent activity around battery recycling in Australia were also among the top talking points
To mark International Day Against Child Labour, Matteo Amerio at Corsearch says the people inside businesses who can identify counterfeiting risks must be given the tools and authority to act
With genuine equity at IP firms becoming rarer, securing partnership is harder than ever, but increased transparency is also making climbing the ladder more predictable
Yossi Sivan explains how Israeli judgment is a pro-brand owner departure from the norm and why it sends a strong message that corporate structures are not always a shield
Halim Shehadeh, group CEO of IP firm CWB, says that in the rush to discuss what AI can do, IP firms are overlooking the more important question of whether they are ready
Caitlin Heard, who formally joined the firm from CMS last month, says she is excited by the ‘energy’ of the London office
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Gift this article